Hoth Therapeutics, Inc. (HOTH), a clinical-stage biopharmaceutical company, said Thursday it has signed a production agreement with Tergus Pharma for both GLP and GMP materials associated with its novel cancer treatment drug, HT-001.
The production agreement comes as Hoth has requested a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration or FDA to discuss a proposed drug development program for the novel treatment.
HT-001 is a topical formulation designed for the treatment of patients with mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are used for treatment of cancers.
HT-001 is targeted to treat these EGFR-induced skin disorders to allow patients to achieve the best potential outcomes of EGFR therapy.
"Hoth management is pleased with the advancement of our HT-001 treatment throughout the developmental process. Patients struggling with dermatological ailments have been known to halt, and even discontinue potentially life-saving oncology treatments," said Robb Knie, CEO of Hoth Therapeutics.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.